Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 5/20 | 0.41 |
| ▸ | SCN9A | Q15858 | 3/20 | 0.37 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.35 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.34 |
| ▸ | FEN1 | P39748 | 1/20 | 0.34 |
| ▸ | FFAR1 | O14842 | 4/20 | 0.34 |
| ▸ | SSTR5 | P35346 | 1/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.34 |
| ▸ | HTR2A | P28223 | 1/20 | 0.33 |
| ▸ | HTR2C | P28335 | 1/20 | 0.33 |
| ▸ | HTR2B | P41595 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11939167 | 0.96 | CNR2 (0.39) | CNR2SCN9AALOX5APFEN1SSTR5 | |
| SCHEMBL11939058 | 0.96 | CNR2 (0.39) | CNR2SCN9AALOX5APFEN1SSTR5 | |
| SCHEMBL10302857 | 0.91 | CNR2 (0.38) | CNR2SCN9AALOX5APFEN1FFAR1 | |
| SCHEMBL12223491 | 0.91 | CNR2 (0.38) | CNR2SCN9AALOX5APFEN1FFAR1 | |
| SCHEMBL10302846 | 0.89 | CNR2 (0.40) | CNR2SCN9APDE4BALOX5APFEN1 | |
| SCHEMBL12223501 | 0.89 | CNR2 (0.40) | CNR2SCN9APDE4BALOX5APFEN1 | |
| SCHEMBL12223582 | 0.89 | GPR119 (0.37) | CNR2SCN9A | |
| SCHEMBL11939218 | 0.88 | FPR2 (0.35) | PDE4BALOX5APFEN1 | |
| SCHEMBL10091383 | 0.88 | CNR2 (0.36) | CNR2SCN9AALOX5APFEN1FFAR1 | |
| SCHEMBL12836512 | 0.88 | CNR2 (0.36) | CNR2PDE4BALOX5APFEN1SSTR5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110240919-A1 | FIVE-RING COMPOUND, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | CHISSO CORPORATION (JP) | 2011-10-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110240919-A1 | FIVE-RING COMPOUND, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | NCAPD3, CCND3, ZKSCAN2 | CNR2 253/4885SCN9A 2120/4885PDE4B 2872/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.